Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study

Declining value of alanine aminotransferase in screening of blood donors to prevent... BACKGROUND: Since the mid‐1980s, blood banks in the United States have screened donors for elevated alanine aminotransferase (ALT) in an effort to prevent posttransfusion hepatitis. The present study was designed to quantitate the residual value of ALT screening following the implementation of hepatitis C virus (HCV) assays. STUDY DESIGN AND METHODS: Two approaches were used. First, a database of 2.3 million donations made by 586,507 volunteer blood donors between 1991 and 1993 was used to compare the incidence of seroconversion to hepatitis B virus (HBV) and HCV marker positivity in donors with elevated ALT values and with normal ALT values. Second, the duration of ALT elevation prior to HBV and HCV seroconversion was determined from 34 well‐documented cases of posttransfusion HBV and HCV; elevated‐ALT window periods were multiplied by rates of HBV and HCV incidence in donors to project the yield of ALT screening. Predictive value and cost‐ effectiveness analyses were also performed to compare the value of ALT screening before and after HCV screening was implemented. RESULTS: Both approaches indicate that ALT testing does not detect HBV in the window phase but does currently identify approximately 3 HCV window‐phase donations per 1 million donations; this contrasts with ALT detection of approximately 1800 HCV‐infectious units per 1 million donations prior to anti‐HCV screening. Currently, only 8 in 10,000 donated units with elevated ALT (negative anti‐HCV) are infected with HCV. The cost of continued ALT screening was estimated at $7,931,000 per quality‐ adjusted year of life saved. CONCLUSION: The yield, predictive value, and cost‐effectiveness of ALT screening of blood donors have declined dramatically with the implementation of progressively improved anti‐HCV assays. ALT screening of volunteer blood donors should be discontinued. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study

Loading next page...
 
/lp/wiley/declining-value-of-alanine-aminotransferase-in-screening-of-blood-PO4L0sDC1d
Publisher
Wiley
Copyright
1995 AABB
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1046/j.1537-2995.1995.351196110893.x
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND: Since the mid‐1980s, blood banks in the United States have screened donors for elevated alanine aminotransferase (ALT) in an effort to prevent posttransfusion hepatitis. The present study was designed to quantitate the residual value of ALT screening following the implementation of hepatitis C virus (HCV) assays. STUDY DESIGN AND METHODS: Two approaches were used. First, a database of 2.3 million donations made by 586,507 volunteer blood donors between 1991 and 1993 was used to compare the incidence of seroconversion to hepatitis B virus (HBV) and HCV marker positivity in donors with elevated ALT values and with normal ALT values. Second, the duration of ALT elevation prior to HBV and HCV seroconversion was determined from 34 well‐documented cases of posttransfusion HBV and HCV; elevated‐ALT window periods were multiplied by rates of HBV and HCV incidence in donors to project the yield of ALT screening. Predictive value and cost‐ effectiveness analyses were also performed to compare the value of ALT screening before and after HCV screening was implemented. RESULTS: Both approaches indicate that ALT testing does not detect HBV in the window phase but does currently identify approximately 3 HCV window‐phase donations per 1 million donations; this contrasts with ALT detection of approximately 1800 HCV‐infectious units per 1 million donations prior to anti‐HCV screening. Currently, only 8 in 10,000 donated units with elevated ALT (negative anti‐HCV) are infected with HCV. The cost of continued ALT screening was estimated at $7,931,000 per quality‐ adjusted year of life saved. CONCLUSION: The yield, predictive value, and cost‐effectiveness of ALT screening of blood donors have declined dramatically with the implementation of progressively improved anti‐HCV assays. ALT screening of volunteer blood donors should be discontinued.

Journal

TransfusionWiley

Published: Nov 12, 1995

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off